MetLife Investment Management LLC Purchases 1,513 Shares of Penumbra, Inc. (NYSE:PEN)

MetLife Investment Management LLC lifted its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,233 shares of the company's stock after buying an additional 1,513 shares during the period. MetLife Investment Management LLC owned about 0.06% of Penumbra worth $5,517,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. UMB Bank n.a. boosted its holdings in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after purchasing an additional 70 shares during the period. Hurley Capital LLC bought a new position in shares of Penumbra during the fourth quarter valued at approximately $56,000. Huntington National Bank lifted its stake in Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after acquiring an additional 154 shares during the period. Mather Group LLC. boosted its holdings in Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its position in Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock valued at $89,000 after purchasing an additional 75 shares during the period. Institutional investors own 88.88% of the company's stock.

Wall Street Analysts Forecast Growth

PEN has been the topic of several research analyst reports. Truist Financial boosted their price target on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a research report on Thursday. Bank of America assumed coverage on Penumbra in a research note on Friday, March 14th. They issued a "buy" rating and a $320.00 target price for the company. UBS Group reaffirmed a "buy" rating and issued a $330.00 price target (up from $320.00) on shares of Penumbra in a research note on Thursday. BTIG Research reissued a "buy" rating on shares of Penumbra in a research report on Thursday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Insider Buying and Selling

In other news, Director Thomas Wilder sold 360 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total value of $95,248.80. Following the transaction, the director now owns 4,533 shares of the company's stock, valued at $1,199,341.14. This trade represents a 7.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 128,446 shares of company stock valued at $35,959,193. 5.00% of the stock is owned by insiders.

Penumbra Stock Performance

NYSE:PEN traded down $0.96 during trading hours on Monday, reaching $298.82. The company had a trading volume of 272,892 shares, compared to its average volume of 424,259. The firm's 50 day moving average price is $276.99 and its 200-day moving average price is $255.22. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 879.24, a PEG ratio of 2.83 and a beta of 0.56. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to analysts' expectations of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Penumbra's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 earnings per share. On average, analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.